glp 1 agonist mechanism of action weight loss A Closer Look at the Dermatological Profile GLP-1 Agonists Tirzepatide's Unique Mechanism of Action

Viking Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company, is advancing a dual GLP-1/GIP agonist, VK2735, for treating obesity for both subcutaneous and oral administration

Rodrigues, A

Key Takeaways Triple agonist mechanism: Retatrutide is the first medication to activate GIP, GLP-1, and glucagon receptors simultaneously GLP-1 component reduces appetite and slows gastric emptying, the core appetite suppression pathway GIP component improves insulin sensitivity and promotes favorable fat distribution Glucagon component increases energy expenditure through thermogenesis and promotes fat breakdown Weight loss: Phase 2 trials showed up to 24.2% weight loss at 48 weeks, compared to tirzepatide (~22%) and semaglutide (~15%) Investigational status: Not FDA-approved

By focusing on a nutrient-rich diet, staying hydrated and listening to your body, you can navigate symptoms like nausea, fatigue and constipation effectively

Ensure the proper balance of acquisition marketing to retention marketing to ensure new customer acquisition and reduce the leaky bucket of existing customers